Related Experiment Video
Updated: Oct 23, 2025
Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis
Linlin Qu1,2,3, Xiaoxuan Ma1,2,3, Daidi Fan1,2,3
1Shaanxi Key Laboratory of Degradable Biomedical Materials, School of Chemical Engineering, Northwest University, Taibai North Road 229, Xi'an, Shaanxi 710069, China.
Abstract:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Our previous reports showed that ginsenoside Rk3 provided excellent efficacy in alleviating the intestinal inflammatory response and protecting the liver, but its mechanism for HCC prevention remains to be explored. Here, the results suggested that Rk3 displayed potent antitumor effects against a dimethyl nitrosamine- and CCl4-induced HCC mouse model. Results revealed that Rk3 application inhibited liver injury, fibrosis, and cirrhosis. In parallel, Rk3 lowered the inflammatory response by decreasing the expression of inflammatory cytokines, inducing apoptosis, and blocking the cell cycle. Meanwhile, Rk3 effectively ameliorated the gut microbiota dysbiosis. Furthermore, correlation analysis revealed that the LPS-TLR4 signaling pathway, which was inhibited by Rk3, plays a key role in preventing HCC. To conclude, our research provides valuable insights into how Rk3 application targets the gut-liver axis and suppresses HCC development, suggesting that Rk3 might be a promising candidate for clinical treatment of HCC.
Insights
Ginsenoside Rk3 shows potent antitumor effects against hepatocellular carcinoma (HCC) by inhibiting liver injury and inflammation. This compound targets the gut-liver axis, offering a promising strategy for HCC prevention and treatment.
Area of Science:
- Hepatology
- Oncology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) is a major global cause of cancer mortality.
- Ginsenoside Rk3 has demonstrated efficacy in mitigating intestinal inflammation and protecting the liver.
- The precise mechanism of Rk3 in HCC prevention requires further elucidation.
Purpose of the Study:
- To investigate the potential of ginsenoside Rk3 (Rk3) in preventing hepatocellular carcinoma (HCC).
- To explore the underlying mechanisms by which Rk3 exerts its chemopreventive effects.
- To evaluate Rk3's impact on liver injury, fibrosis, inflammation, and gut microbiota.
Main Methods:
- A mouse model of HCC was induced using dimethyl nitrosamine and carbon tetrachloride (CCl4).
- Rk3 was administered to assess its effects on liver pathology and tumor development.
- Analysis included inflammatory cytokine expression, apoptosis, cell cycle progression, and gut microbiota composition.
- Correlation analysis was performed to identify key signaling pathways involved.
Main Results:
- Rk3 significantly inhibited liver injury, fibrosis, and cirrhosis in the HCC mouse model.
- Rk3 reduced inflammatory responses by decreasing cytokine expression and inducing apoptosis.
- Rk3 application led to the amelioration of gut microbiota dysbiosis.
- Inhibition of the LPS-TLR4 signaling pathway by Rk3 was identified as crucial for HCC prevention.
Conclusions:
- Ginsenoside Rk3 demonstrates potent antitumor effects against HCC in a preclinical model.
- Rk3 acts by targeting the gut-liver axis, modulating inflammation, and improving gut microbiota.
- The findings suggest Rk3 is a promising candidate for clinical development in HCC treatment.
